A group of anticardiolipin antibodies (aCL) require β2-glycoprotein I (β2GPI) to recognize their target, which might be located on endothelial cells (EC) and/or platelets. Following incubation with epithelial cells, 13 of 30 lupus sera retained EC-reactive antibodies of the IgG, IgA and IgM isotypes. Associated aCL and anti-phosphatidylethanolamine antibodies were partly absorbed on eC as well as EC. The former antibodies were more efficiently removed in the presence than in the absence of the latter. The presence of β2GPI in the affinity-purified aCL preparations may explain their binding to EC, as this cross-reaction was abrogated by the removal of the cofactor and restored by its re-introduction. Seventy four per cent of EC were faintly stained with polyclonal or monoclonal antibody directed to the cofactor. The β 2GPI mediated aCL binding to EC membranes could thus be influential in the development of thrombosis and/or thrombocytopenia in aCL-positive patients.
Hughes Grv.The antiphospholipid syndrome: ten years on. Lancet1993; 2: 341-344.
2.
Alarcón-Segovia D., Cabral ARFunctional and immunochemical heterogeneity of antiphospholipid antibodies: a classification. J Rheumatol1992; 19: 1166-1169.
3.
McNeil HP et al. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apoliprotein H). Proc Natl Acad Sci USA1990; 87: 4210-4214.
4.
Galli M. et al. Anticardiolipin antibodies directed not to cardiolipin, but to a plasma protein cofactor. Lancet1990; 1: 1544-1547.
5.
Hunt JEet al. A phospholipid-β2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease, but not with infection. Lupus1992; 1: 75-81.
6.
Vlachoyiannopoulos PG et al. Antibodies to phosphatidylethanolamine in antiphospholipid syndrome and systemic lupus erythematosus: their correlation with anticardiolipin antibodies β2-glycoprotein I plasma levels. Autoimmunity1993; 16: 245-249.
7.
Hughes Grv.Thrombosis, abortion, cerebral disease and the lupus anticoagulant. Br Med J1983; 287: 1088-1089.
8.
Alarcón-Segovia D. et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. a prospective study of 500 consecutive patients. Medicine1989 ; 68: 353-365.
9.
McNeil HP, Chesterman CN, Krilis SAImmunology and clinical importance of antiphospholipid antibodies. Adv Immunol1991; 49: 193-280.
10.
Shingu M., Hurd ERSera from patients with systemic lupus erythematosus reactive with human endothelial cells. J Rheumatol1981: 8: 581-586.
11.
Cines BD et al. Presence of complement-fixing and anti-endothelial antibodies in systemic lupus erythematosus. J Clin Invest1984; 73: 611-625.
12.
Le Tonquèze M. et al. The relationship of anti-endothelial cell antibodies to anti-phospholipid antibodies in patients with giant cell arteritis and/or polymyalgia rheumatica. Autoimmunity (in press).
13.
Vismara A. et al. Relationship between anti-cardiolipin and antiendothelial cell antibodies in systemic lupus erythematosus. Clin Exp Immunol1988; 74: 247-253.
14.
Hasselaar P, DerksenRHWM, Blokzijl L, de Groot PG. Crossreactivity of antibodies directed against cardiolipin, DNA, endothelial cells and blood platelets. Thromb Haemost1990; 63: 169-173.
15.
Cervera R. et al. Antiendothelial cell antibodies in patients with the antiphospholipid syndrome. Autoimmunity1991; 11: 1-6.
16.
McGrae KR et al. Detection of endothelial cell-reactive immunoglobulin in patients with anti-phospholipid antibodies. Br J Haematol1991; 79: 595-605.
17.
Vázquez-Mellado J. et al. Exposure of anionic phospholipids upon platelet activation permits binding of β2-glycoprotein I and through it that of IgG antiphospholipid antibodies. Studies in platelets from patients with antiphospholipid syndrome and normal subjects. J Autoimmun1994; 7: 335-348.
18.
Carreras LO et al. Arterial thrombosis, intrauterine death and 'lupus' anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet1981; 1: 244-246.
19.
Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271-1277.
20.
Bakimer R. et al. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody. J Clin Invest1992; 89: 1558-1563.
21.
Adler Y., Salozhin K., Le Tonquèze M., Shoenfeld Y., Youinou P.Antiendothelial cell antibodies: a need for standardization. Lupus1994; 3: 77-84.
22.
Edgell CJ, cDonald CC, Graham JB. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci USA1983, 80: 3734-3737.
23.
Edgell CJ, Gazdar AF, Minna JDExpression of feline xenotropic RNA tumor virus in hybrids between permissive human and non-permissive mouse cells. Int J Cancer1979; 24: 826-834.
24.
Rosenbaum J. et al. Measurement and characterization of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol1988; 72: 450-456.
25.
Youinou P., Blanc JJ, Salaun G., Lamour A.Antibodies to cardiolipin in ischaemic heart disease. Eur J Intern Med1993; 4: 53-56.
26.
Hunt JE, Simpson RJ. Krilis SAIdentification of a region of β2-glycoprotein I critical for lipid binding and anticardiolipin antibody cofactor activity. Proc Natl Acad Sci USA1993; 90: 2141-2145.
27.
Westerman EM et al. Neuropathologic findings in multi-infarct dementia associated with anticardiolipin antibody. Evidence for endothelial injury as the primary event. Arthritis Rheum1992; 35: 1038-1041.
28.
Sedmak DD et al. Expression of IgG Fc receptor antigens in placenta and on endothelial cells in humans. An immunohistochemical study. Am J Pathol1991; 138: 175-181.
29.
Takumura H. , Kasai H., Anita H., Kito M.Phospholipid molecular species in human umbilical artery and vein endothelial cells. J Lipid Res1990: 31: 709-717.
30.
Arvieux J. et al. Reactivity patterns of anti-phospholipid antibodies in SLE sera in relation to erythrocyte binding and complement activation. Clin Exp Immunol1991; 84: 466-471.
31.
Harris EN et al. Crossreactivity of antiphospholipid antibodies. J Clin Lab Immunol1985; 16: 1-6.
32.
Guamar T. et al. Lysophosphatidylethanolamine is the antigen to which apparent antibody to phosphatidylethanolamine binds. J Clin Immunol1990; 10: 200-203.
33.
Rauch J. Janoff ASPhospholipid in the hexagonal II phase is immunogenic: evidence for immunorecognization of nonbilayer lipid phases in vivo. Proc Natl Acad Sci USA1990; 87: 4112-4114.
34.
Vossen Rcrm et al. Long-term fatty acid modification of endothelial cells: implications for arachidonic acid distribution in phospholipid classes. J Lipid Res1993; 34: 409-420.
35.
Viard JP, Amoura Z., Bach JFAssociation of anti-β2-glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med1992 ; 93: 181-186.
